Tag Archives: Cory Kasimov

Analysts Conflicted on These Healthcare Names: Bluebird Bio (NASDAQ: BLUE), Argenx Se (NASDAQ: ARGX) and Ironwood Pharma (NASDAQ: IRWD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (BLUE – Research Report), Argenx Se (ARGX – Research Report) and Ironwood Pharma (IRWD – Research Report). Bluebird Bio (BLUE) J.P.

BioMarin Pharmaceutical Inc. (BMRN) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin Pharmaceutical Inc. (BMRN – Research Report) on August 2 and set a price target of $133. The company’s shares closed on Friday at $77.84, close to its 52-week low

Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Irhythm Technologies (IRTC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Irhythm Technologies (IRTC – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) J.P. Morgan analyst

Gilead Sciences (GILD) Receives a Buy from J.P. Morgan

In a report released yesterday, Cory Kasimov from J.P. Morgan assigned a Buy rating to Gilead Sciences (GILD – Research Report), with a price target of $85. The company’s shares closed yesterday at $67.09. According to TipRanks.com, Kasimov is a

Incyte Corp (INCY) Receives a Buy from J.P. Morgan

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Incyte Corp (INCY – Research Report), with a price target of $91. The company’s shares closed yesterday at $85.43, close to its 52-week high of

J.P. Morgan Maintains Their Buy Rating on Gilead Sciences (GILD)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $64.91. According to TipRanks.com, Kasimov is a 3-star analyst with an average return